Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model

References

• Alonen A, Finel M, Kostiainen R. (2008). The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol 76:763–72. https://doi.org/10.1016/j.bcp.2008.07.006
   PubMed Web of Science ®Google Scholar
• Aquilante CL, Kosmiski LA, Bourne DWA, et al. (2013). Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol 75:217–26. https://doi.org/10.1111/j.1365-2125.2012.04343.x
   PubMed Web of Science ®Google Scholar
• Bae J-W, Jang C-G, Lee S-Y. (2011). Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. J Clin Pharmacol 51:1704–11. https://doi.org/10.1177/0091270010388651
   PubMed Web of Science ®Google Scholar
• Baer BR, DeLisle RK, Allen A. (2009). Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem Res Toxicol 22:1298–309. https://doi.org/10.1021/tx900105n
   PubMed Web of Science ®Google Scholar
• Bosilkovska M, Samer CF, Déglon J, et al. (2014). Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther 96:349–59. https://doi.org/10.1038/clpt.2014.83
   PubMed Web of Science ®Google Scholar
• Böttiger Y, Tybring G, Götharson E, Bertilsson L. (1997). Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 62:384–91. https://doi.org/10.1016/S0009-9236(97)90116-8
   PubMed Web of Science ®Google Scholar
• Buchheit D, Dragan C-A, Schmitt EI, Bureik M. (2011). Production of ibuprofen acyl glucosides by human UGT2B7. Drug Metab Dispos Biol Fate Chem 39:2174–81. https://doi.org/10.1124/dmd.111.041640
   PubMed Web of Science ®Google Scholar
• Crespi CL, Penman BW. (1997). Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug–drug interactions. Adv Pharmacol San Diego Calif 43:171–88
   PubMedGoogle Scholar
• Dong D, Wu B, Chow D, Hu M. (2012). Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metab Rev 44:192–208
   PubMed Web of Science ®Google Scholar
• EMA. (2012). Guideline on the investigation of drug interactions. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
   Google Scholar
• FDA. (2012). Guidance for industry: drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations
   Google Scholar
• FDA. (2017). Guidance for industry. In vitro metabolism and transporter mediated drug-drug interaction studies. Available from: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm581965.pdf
   Google Scholar
• Fowler S, Zhang H. (2008). In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. Aaps J 10:410–24. https://doi.org/10.1208/s12248-008-9042-7
   PubMed Web of Science ®Google Scholar
• Gibbons JA, de Vries M, Krauwinkel W, et al. (2015). Pharmacokinetic drug interaction studies with Enzalutamide. Clin Pharmacokinet 54:1057–69. https://doi.org/10.1007/s40262-015-0283-1
   PubMed Web of Science ®Google Scholar
• Godoy P, Hewitt NJ, Albrecht U, et al. (2013). Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:1315–530. https://doi.org/10.1007/s00204-013-1078-5
   PubMed Web of Science ®Google Scholar
• Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, et al. (2011). Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol 71:72–87
   PubMed Web of Science ®Google Scholar
• Härtter S, Grözinger M, Weigmann H, et al. (2000). Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 67:1–6. https://doi.org/10.1067/mcp.2000.104071
   PubMed Web of Science ®Google Scholar
• Hemeryck A, De Vriendt CA, Belpaire FM. (2001). Metoprolol-paroxetine interaction in human liver microsomes: stereoselective aspects and prediction of the in vivo interaction. Drug Metab Dispos Biol Fate Chem 29:656–63
   PubMed Web of Science ®Google Scholar
• Hesse LM, Venkatakrishnan K, Court MH, et al. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos Biol Fate Chem 28:1176–83
   PubMed Web of Science ®Google Scholar
• Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. (2011). Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther 89:579–86. https://doi.org/10.1038/clpt.2010.358
   PubMed Web of Science ®Google Scholar
• Huang S-M, Rowland M. (2012). The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther 91:542–9. https://doi.org/10.1038/clpt.2011.320
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Ring BJ, Anderson SR. (2015). Low-turnover drug molecules: a current challenge for drug metabolism scientists. Drug Metab Dispos 43:1917–28
   PubMed Web of Science ®Google Scholar
• Hynninen V-V, Olkkola KT, Leino K, et al. (2006). Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. Antimicrob Agents Chemother 50:1967–72. https://doi.org/10.1128/AAC.01483-05
   PubMed Web of Science ®Google Scholar
• Iga K. (2015). Simulation of metabolic drug-drug interactions perpetrated by Fluvoxamine using Hybridized two-compartment Hepatic Drug-Pool-based tube modeling and estimation of in vivo inhibition constants. J Pharm Sci 104:3565–77. https://doi.org/10.1002/jps.24549
   PubMed Web of Science ®Google Scholar
• Kang BC, Yang CQ, Cho HK, et al. (2002). Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos 23:77–81
   PubMed Web of Science ®Google Scholar
• Kazierad DJ, Martin DE, Blum RA, et al. (1997). Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 62:417–25. https://doi.org/10.1016/S0009-9236(97)90120-X
   PubMed Web of Science ®Google Scholar
• Moody GC, Griffin SJ, Mather AN, et al. (1999). Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica Fate Foreign Compd Biol Syst 29:53–75. https://doi.org/10.1080/004982599238812
   PubMed Web of Science ®Google Scholar
• Mori K, Hashimoto H, Takatsu H, et al. (2009). Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica Fate Foreign Compd Biol Syst 39:415–22. https://doi.org/10.1080/00498250902822204
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, et al. (2001). Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 69:194–200. https://doi.org/10.1067/mcp.2001.114229
   PubMed Web of Science ®Google Scholar
• Niemi M, Tornio A, Pasanen MK, et al. (2006). Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 62:463–72. https://doi.org/10.1007/s00228-006-0133-z
   PubMed Web of Science ®Google Scholar
• Njuguna NM, Umehara K-I, Huth F, et al. (2016). Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction. Drug Metab Pers Ther 31:221–8. https://doi.org/10.1515/dmpt-2016-0028
   PubMedGoogle Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
   PubMed Web of Science ®Google Scholar
• Obach RS, Cox LM, Tremaine LM. (2005). Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos Biol Fate Chem 33:262–70. https://doi.org/10.1124/dmd.104.002428
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Torres R, Dressman MA, et al. (2015). Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol 55:1004–11. https://doi.org/10.1002/jcph.507
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Usuki E, Yerino P, Parkinson A. 2008. In Vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the tabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. In: Rodrigues AD, ed. Drug–drug interactions, drugs and the pharmaceutical sciences. New York: Informa Healthcare, 231–358
   Google Scholar
• Olkkola KT, Backman JT, Neuvonen PJ. (1994). Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481–5
   PubMed Web of Science ®Google Scholar
• Parmentier Y, Bossant M-J, Bertrand M, Walther B. (2007). In vitro studies of drug metabolism. In: Reedijk J, ed. Chemistry, Molecular sciences and chemical engineering, from comprehensive medicinal chemistry II. Waltham: Elsevier, Volume 5, 231–57
   Google Scholar
• Parmentier Y, Pothier C, Delmas A, et al. (2017). Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model. Xenobiotica Fate Foreign Compd Biol Syst 47:562–75. https://doi.org/10.1080/00498254.2016.1208854
   PubMed Web of Science ®Google Scholar
• Perloff ES, Mason AK, Dehal SS, et al. (2009). Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica Fate Foreign Compd Biol Syst 39:99–112. https://doi.org/10.1080/00498250802638155
   PubMed Web of Science ®Google Scholar
• Rendic S, Guengerich FP. (2015). Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. Chem Res Toxicol 28:38–42
   PubMed Web of Science ®Google Scholar
• Rowland M, Matin SB. (1973). Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1:553–67
   Google Scholar
• Richter T, Schwab M, Eichelbaum M, Zanger UM. (2005). Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem Pharmacol 69:517–24. https://doi.org/10.1016/j.bcp.2004.10.008
   PubMed Web of Science ®Google Scholar
• Roy P, Yu LJ, Crespi CL, Waxman DJ. (1999). Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos Biol Fate Chem 27:655–66
   PubMed Web of Science ®Google Scholar
• Ruwe FJL, Smulders RA, Kleijn HJ, et al. (2001). Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 16:449–59. https://doi.org/10.1002/hup.318
   PubMed Web of Science ®Google Scholar
• Sai Y, Dai R, Yang TJ, et al. (2000). Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica Fate Foreign Compd Biol Syst 30:327–43. https://doi.org/10.1080/004982500237541
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Beal SL. (1981). Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503–12
   PubMedGoogle Scholar
• Stout SM, Nielsen J, Bleske BE, et al. (2010). The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. J Cardiovasc Pharmacol Ther 15:373–9
   PubMed Web of Science ®Google Scholar
• Troost J, Tatami S, Tsuda Y, et al. (2011). Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol 72:247–56. https://doi.org/10.1111/j.1365-2125.2011.03988.x
   PubMed Web of Science ®Google Scholar
• Uttamsingh V, Gallegos R, Liu JF, et al. (2015). Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine. J Pharmacol Exp Ther 354:43–54. https://doi.org/10.1124/jpet.115.223768
   PubMed Web of Science ®Google Scholar
• Varhe A, Olkkola KT, Neuvonen PJ. (1996). Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 42:465–70
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Moltke LLV, Greenblatt DJ. (1998). Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci 87:1502–7. https://doi.org/10.1021/js980255z
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Harmatz JS, et al. (2000). Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos 28:1493–504
   PubMed Web of Science ®Google Scholar
• Wang RW, Newton DJ, Liu N, et al. (2000). Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos Biol Fate Chem 28:360–6
   PubMed Web of Science ®Google Scholar
• Wienkers L, Stevens J. 2003. Cytochrome P450 reaction phenotyping. In: Lee J, Obach RS, Fisher MB, eds. Drug metabolizing enzymes: cytochrome P450 and other enzymes in drug discovery and development. New York: FontisMedia SA, 255–310
   Google Scholar
• Winnenburg R, Bodenreider O. (2014). A framework for assessing the consistency of drug classes across sources. J Biomed Semantics 5:30. https://doi.org/10.1186/2041-1480-5-30
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Turvy CG, et al. (1997). Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos Biol Fate Chem 25:168–74
   PubMed Web of Science ®Google Scholar
• Yang X, Atkinson K, Di L. (2016). Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method. Drug Metab Dispos 44:460–5
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Takahata T, Nakagami T, et al. (2004). Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57:487–94. https://doi.org/10.1111/j.1365-2125.2003.02047.x
   PubMed Web of Science ®Google Scholar
• Yoshizato T, Kotegawa T, Imai H, et al. (2012). Itraconazole and domperidone: a placebo-controlled drug interaction study. Eur J Clin Pharmacol 68:1287–94. https://doi.org/10.1007/s00228-012-1258-x
   PubMed Web of Science ®Google Scholar
• Zhang H, Davis CD, Sinz MW, Rodrigues AD. (2007). Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667–87. https://doi.org/10.1517/17425255.3.5.667
   PubMed Web of Science ®Google Scholar
• Zhou HH, Anthony LB, Roden DM, Wood AJ. (1990). Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther 47:686–93
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Lim LY, et al. (2004). Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5:415–42
   PubMed Web of Science ®Google Scholar